Secondary Cancers Resurface In Updated Revlimid Maintenance Trial Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Trial investigators proclaim the drug's benefits outweigh its risks and predict maintenance will become the standard of care in multiple myeloma, but investors remain unconvinced.
You may also be interested in...
Celgene Flexes Its Muscles
In five short years, Celgene has used the cash from the blockbuster success of its flagship product Revlimid to pursue a wide range of deals for revenues now and new markets later. Its homegrown R&D has created a bountiful late-stage pipeline. It’s projecting even more Revlimid success in the next few years. So why aren’t investors buying?
Revlimid In Limbo: Market Slams Celgene, Physicians And Payers Take Wait And See Approach
Absent proof of an overall survival benefit, new data suggesting a link between longer-term use of Celgene Corp.’s blockbuster Revlimid and secondary malignancies in multiple myeloma may encourage a cautious approach to maintenance treatment, threatening a major expansion for the drug.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.